From CES to JPM: When Innovation Meets Trust

Why this issue exists

CES shows what technology can do. JPM shows what the market will allow it to do. Between those two moments sits commercialization — the point where ambition meets accountability, and where trust ultimately decides what scales and what stalls.

Curb moment: Innovation loves speed. Healthcare prefers explanations… preferably in writing.

The Primary Signal: Trust Has Overtaken Technology

At CES 2026, the dominant story was capability — the sheer physical power of AI in robotics and biowearables. At JPM 2026, the conversation shifted to permission — the regulatory and clinical "green light" required to move from experimental code to enterprise infrastructure.

The sector is no longer debating if AI works. It's deciding whether AI can be relied upon — clinically, operationally, and financially. This shift is reshaping capital allocation and procurement in real time, as buyers move from AI as "augmentation" to AI as orchestration.

Curb moment: The model is impressive. The liability is still a group project.

Capital Discipline: The $14.2B "Clearing Event"

JPM 2026 felt like a reality check for the long-anticipated TechBio reset. Digital health funding reached $14.2 billion in 2025 (up 35% YoY), the highest since 2022 — but power is concentrating rapidly in a small "winner class."

The AI Premium: AI-enabled companies captured 54% of total funding.

The Valuation Gap: AI-centric startups commanded a 19% average deal-size premium, which skyrocketed to 61% at Series C.

Curb moment: The check cleared. Just not for everyone.

Policy Signals: Lighter Touch, Heavier Debt

Federal leadership signaled a future of "radical transparency" and regulatory flexibility, paired with a massive financial asterisk.

The "Loyal AI Agent" vision: HHS Deputy Secretary Jim O'Neill predicts every adult will eventually have a personal AI agent "loyal to them" to manage health advice and data.

The hard truth: The One Big Beautiful Bill (OBBB) Act includes a $50 Billion Rural Health Transformation Program, but this is offset by a staggering $1 Trillion Medicaid cut over 10 years.

Translation: Flexibility upstream, pressure downstream.

Curb moment: Less regulation. More math.

From Pilots to Performance

Buyers at JPM expressed near-zero tolerance for "innovation theater." The focus has shifted to Operational UX — redesigning workflows so automation improves productivity without adding friction to an already burned-out workforce (where 43% of primary care providers are already at their limit).

Clinical standards: Wearables are moving from "insight" to "action." The Abbott–Medtronic MiniMed 780G integration now adjusts insulin every five minutes in real time based on continuous data.

RCM excellence: Waystar showcased agentic AI simplifying revenue cycle workflows, turning administrative tasks into direct margin levers.

Curb moment: If it adds a dashboard, it's not helping.

Pharma's Shift: From Experiments to Factories

Biopharma is industrializing decision-making. The $1 Billion, five-year Eli Lilly–NVIDIA partnership to build a co-innovation lab signals that AI is no longer a science project — it's factory infrastructure for drug discovery.

This is what trust looks like at scale: repeatability, rigor, and shared accountability.

Curb moment: When AI becomes infrastructure, excuses lose their funding.

Commercial Corner: 3 Signals for the 2026 Sales Force

In a market defined by governed commercial execution, the traditional pitch is officially obsolete.

Stop selling tools. Start selling operating margin. Hospital CIOs are prioritizing cost containment and old-fashioned ROI. If your solution can't connect clinical data to financial impact, it will be treated as noise, not a priority.

Speed is the new moat. Top performers are using Tender and Contracts AI to compress sales cycles and increase bid throughput without sacrificing compliance. If your RFP response takes weeks, the deal is already gone.

Sell the inside-out transformation. As VC firms like General Catalyst acquire legacy systems (like Summa Health) to transform them internally, the buyer may no longer be the "Innovation Lead" — it may be the platform owner who just bought the entire system.

Curb moment: Selling confidence still beats selling capability.

JPM 2026 Speaker Grid (Strategic Highlights)

Jim O'Neill, HHS (Government): "Loyal AI Agent" vision & streamlining FDA hurdles.

Matt Hawkins, Waystar (RCM / Fintech): Agentic AI for RCM and direct margin improvement.

David Ricks, Eli Lilly (Pharma): $1B "AI Factory" for drug discovery & LillyDirect scale.

Ryan Smith, Intermountain (Health System): Consolidating 8 EHRs into Epic; methodical AI governance.

Rohit Chandra, Cleveland Clinic (Health System): "Healthcare company, not a tech company"; partnership AI.

Aaron Patzer, Vital (Innovator): Emergence of "patient-facing AI standards" to build trust.

The Lab Note: Let's Talk Signals

This isn't just about the signals I'm seeing — it's about the ones you're catching on the front lines. Did you attend CES or JPM? Did the "Trust over Technology" shift show up in your conversations? Are "agentic AI" requirements now appearing in your RFPs?

No hype. No promotion. Just signals.